Business Wire

SISVEL-GROUP

Share
A Final Victory for Sisvel Before the German Federal Supreme Court (BGH) In the Sisvel vs. Haier Case

On May 5 the German Federal Supreme Court heard the arguments in the case between Sisvel and Haier regarding Sisvel’s request for injunctive relief for infringement of cellular standard essential patents (SEPs) owned by Sisvel. The decision rendered on May 5, marks the final decision on the infringement of Sisvel’s European patent EP 0 852 885 (“EP 885”), and the related FRAND defense after a 6 year long legal dispute.

Prior to this verdict, on March 10, 2020 the BGH had already given final confirmation that Sisvel’s EP 885 should be considered valid. The nullity actions had been filed by Haier and ZTE. On April 28, 2020 there was a subsequent decision by the BGH confirming the validity of Sisvel’s European patent EP 1 264 504, where Haier and ZTE were likewise the plaintiffs. Last but not least, yesterday the BGH ruled that in the infringement proceedings of EP 885 the decision of the Appeal Court in Düsseldorf from March 2017 is reversed in relation to the finding on costs and insofar as the decision has found to the detriment of the plaintiff, i.e. Sisvel.

“Sisvel welcomes the results we have obtained in the recent weeks before the highest court for patent matters in Germany. Whilst we still see a too much hold-out and “efficient infringement” strategies being used, we have every confidence that Haier and implementers alike will take notice of this landmark decision.” said Florian Cordes, who managed the litigation for Sisvel, “We also trust that the decision of the BGH will provide certain instructions to the market and courts how implementers of SEPs should behave, which may prevent future disputes.”

The patents asserted against Haier are part of Sisvel’s bilateral “Wireless” program and are available under license with its “Mobile Communication Program” (MCP) as well. The Sisvel MCP is a licensing platform that licenses cellular (2G, 3G, 4G) standard essential patents, which are owned by a variety of companies, including Airbus DS, KPN, Mitsubishi Electric, Orange, Sisvel and 3G Licensing.

For additional information about the program, please visit the dedicated section of our website: https://www.sisvel.com/licensing-programs/wireless-communications/mcp/introduction

About Sisvel

Sisvel is a world leader in fostering innovation and managing intellectual property. The Group identifies, evaluates and maximizes the value of IP assets for its partners around the world, providing firms with a revenue stream which can be reinvested in innovation for the generation of future revenues. Founded in 1982, the Group is headquartered in Luxembourg and has subsidiaries in China, Germany, Italy, Japan, Spain, the United States and the United Kingdom. The Group has a long history of managing successful patent portfolios including those related to the audio compression standards known as MP3 and MPEG Audio, as well as broadcasting and receiving of digital terrestrial television standards maintained by the DVB Project. Sisvel currently operates patent pools and joint licensing programs in the fields of mobile communication; wireless local area networking 802.11; digital video broadcasting; recommendation engine and broadband access to data networks.

For additional information, please visit: www.sisvel.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ookla Unveils Speedtest Pulse™, Redefining Network Validation and Troubleshooting10.11.2025 12:00:00 CET | Press release

Disruptive new diagnostic device puts 20 years of network expertise in the hands of ISPs and enterprises, empowering them to validate performance, end costly repeat visits, and boost customer satisfaction. Ookla®, a global leader in connectivity intelligence, today unveiled Speedtest Pulse™, a new network diagnostic device designed to provide definitive, smartphone-based validation and troubleshooting for internet service providers (ISPs) and enterprises. Leveraging the power of Speedtest®, a globally trusted gold standard for connectivity measurement, Speedtest Pulse bridges a crucial gap in technician toolkits, offering a powerful, scalable solution that is easy to use and provides clear, actionable insights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251110605367/en/ Speedtest Pulse™ is a dual-mode network diagnostic tool offering one-tap, smartphone-based validation and troubleshooting, and autonomous testing of netw

Kaneka Expands Global Reach with i-ED COIL™ Launch in Europe10.11.2025 03:51:00 CET | Press release

Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Kazuhiko Fujii) (TOKYO:4118) has begun sales of its i-ED COIL™, a brain aneurysm embolization coil (*1), in Europe as of October. The product obtained EC certification (*2) under an EU Medical Device Regulation (*3) in July and will be distributed primarily in Europe through Kaneka Medical Europe N.V. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251109744229/en/ i-ED Coil The i-ED COIL™ provides world-class flexibility, enabled by its specialized wire thickness and structural features. This flexibility enables coils to be packed more densely within aneurysms than conventional products and allows treatment of aneurysms with irregular shapes. Its role in reducing the risk of aneurysm rupture is highly regarded by physicians, and since its launch in the Japanese market in 2019, sales have continued to grow steadily. Kaneka is expanding its business in a wide range

Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week8.11.2025 23:15:00 CET | Press release

- 48-week data show a 64% decrease from baseline in proteinuria in IgA nephropathy, 82% decrease from baseline in proteinuria in primary membranous nephropathy, and stabilization of estimated glomerular filtration rate across both diseases - - Vertex on track to initiate rolling submission of Biologics License Application for potential accelerated approval to the U.S. Food and Drug Administration this year; full enrollment completed for Phase 3 RAINIER trial in IgA nephropathy - - Povetacicept in primary membranous nephropathy granted Fast Track Designation by the U.S. Food and Drug Administration and Phase 2/3 pivotal trial initiated - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced updated data for povetacicept (pove) in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) from the ongoing RUBY-3 trial at the American Society of Nephrology (ASN) Kidney Week 2025 in Houston, Texas. Pove is an investigational recombinant fusion protein therapeutic and dual

Westinghouse and Hungary Establish Landmark Nuclear Fuel Partnership8.11.2025 15:00:00 CET | Press release

First Contract Signed with MVM Group to Deliver VVER-440 Fuel to Paks Nuclear Power Plant Westinghouse Electric Company and MVM Group signed a contract to ensure diversification of fuel supply in Hungary. This partnership brings to Paks Nuclear Power Plant (NPP) reliable supply with Westinghouse VVER fuel, manufactured in Europe. The Westinghouse VVER-440 fuel reload deliveries will start in 2028, subject to licensing activities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251107682814/en/ Westinghouse Nuclear Fuel Senior Vice President Aziz Dag, left, and Károly Mátrai, CEO of the MVM Group, signed the Paks VVER-440 contract, Nov. 7, 2025. “Our agreement with Westinghouse is a clear response to today's energy challenges and further strengthens the role of Hungary's leading base power plant in the domestic energy supply. This strategically important step will make the operation of Paks Nuclear Power Plant safer and more f

OMRON Releases the “Medium-Term Roadmap SF 2nd Stage”8.11.2025 07:00:00 CET | Press release

OMRON (TOKYO: 6645) has announced its “Medium-Term Roadmap Shaping the Future 2nd Stage (“SF 2nd Stage”),” covering from FY2026 to FY2030, on November 7, 2025 (JST). This Roadmap presents the Group’s vision and growth strategies through 2030, which are disclosed on our corporate website. Overview of the “Medium-Term Roadmap SF 2nd Stage” Since April 2024, OMRON has been implementing a Structural Reform Program “NEXT 2025” aimed at rebuilding our foundation for profitability and growth. With the completion of this Program in September 2025, we have shifted into a growth phase and formulated a new Roadmap looking ahead to 2030. This Roadmap identifies Business Portfolio Restructuring as a core strategy. We have defined Thirteen Focus Businesses to drive the Group’s future growth. By accelerating our selection and concentration efforts, we aim to build a “distinctive” business portfolio that maximizes overall Group growth. Furthermore, to maximize the growth potential of our Focus Busines

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye